

For those who can't make a meal of it



Regulan

Regulan

3 SACHETS DAILY EASY MIX

Ispaghula Husk B.P.

for the bulk of dietary constipation

Prescribing Information. **Presentation** Premeasured, single-dose sachet containing 6.4 g of beige rough ground powder. Active ingredient - 56% (3.6 g) Ispaghula Husk B.P. **Uses** For the treatment of constipation and patients requiring a high fibre regimen. **Dosage and Administration** 1. Pour measured dosage into a glass. 2. Slowly add 150 ml (4 ptl) COOL water. 3. Drink entire contents immediately. An additional glass of liquid may be taken if needed. **Adults and children over 12 years** The usual dosage is the entire contents of one sachet taken one to three times daily. **Children A** reduced dosage based upon the age and size of the child should be given. 6-12 years 1/2-1 level 5 ml teaspoonful one to three times daily. **Contraindications:** Intestinal obstruction, faecal impaction, hypersensitivity to ispaghula. **Warnings and Precautions:** Intestinal atony or stenosis, diabetes. Should be taken as a liquid suspension and drunk immediately after mixing. **Adverse effects:** Allergy and gastrointestinal obstruction or impaction have been reported with hydrophilic mucilloid preparations. **Product Licence Holder and Number** G.D. Searle & Co. Ltd. 0020/0087 **Basic N.H.S. cost** Box of 30 sachets £2.10. Full prescribing information is available on request. Regulan and Searle are trademarks. RE JA13 January 1983



Gold Cross Pharmaceuticals Division of G. D. Searle and Co. Ltd. P.O. Box 53, Lane End Road, High Wycombe, Bucks HP12 4HL Telephone: High Wycombe 21124

Presentation White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use. Satisfactory response usually occurs within five to seven days. **Contra-indications, warnings, etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulas. General precautions common to all corticosteroid therapy should be observed during treatment with 'Colifoam'. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Do not refrigerate, incinerate or puncture the aerosol can. Shake vigorously before use. Keep out of reach of children. **Package quantities** Aerosol canister containing 20g (14 applications) plus a plastic applicator and illustrated leaflet. One applicatorful of 'Colifoam' provides a dose of approximately 90-110mg. of hydrocortisone acetate, similar to that used in a retention enema for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Basic NHS cost** 20g (14 applications) plus applicator, £7.58. **Product licence no.** 0036/0021. **References** 1. Ruddlel WSJ et al. Gut 1980; 21: 885-889. 2. O'Donoghue D. Modern Medicine, December 1981; 45: 3. Source: MIMS Nov. 1982. Further information is available on request. Stafford-Miller Ltd, Professional Relations Division, Hatfield, Hertfordshire AL10 0NZ.

Pres ace to a 2
less aerosol foam containing hydrocortisone acetate PhEur 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use. Satisfactory response usually occurs within five to seven days. **Contra-indications, warnings, etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulas. General precautions common to all corticosteroid therapy should be observed during treatment with 'Colifoam'. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Do not refrigerate, incinerate or puncture the aerosol can. Shake vigorously before use. Keep out of reach of children. **Package quantities** Aerosol canister containing 20g (14 applications) plus a plastic applicator and illustrated leaflet. One applicatorful of 'Colifoam' provides a dose of approximately 90-110mg. of hydrocortisone acetate, similar to that used in a retention enema for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Basic NHS cost** 20g (14 applications) plus applicator, £7.58. **Product licence no.** 0036/0021. **References** 1. Ruddlel WSJ et al. Gut 1980; 21: 885-889. 2. O'Donoghue D. Modern Medicine, December 1981; 45: 3. Source: MIMS Nov. 1982. Further information is available on request. Stafford-Miller Ltd, Professional Relations Division, Hatfield, Hertfordshire AL10 0NZ.



IT WORKS

COLIFOAM is as effective as traditional steroid enemas.^{1,2}

It has also been shown to have inherently superior retentive properties!¹



PATIENTS PREFER IT

COLIFOAM is known to be far more comfortable, convenient and acceptable to the patient.

It causes less distress to administer and less interference in patients' lives!¹

IN DISTAL INFLAMMATORY BOWEL DISEASE

COLIFOAM
hydrocortisone acetate foam



The fast, simple and
promote peptic

FOR PRESCRIBING INFORMATION SEE OVERLEAF

And specific way to ulcer healing



80% ulcers healed in one month¹

Rapid relief of pain, rapid healing of the ulcer.

No dosage simpler in peptic ulcer treatment

Specifically developed as b.d. treatment.

The benefits of highly specific H₂ blockade

Zantac treatment has not been shown to affect the central nervous system,^{1,2} to exert anti-androgenic effects^{3,4} or to cause drug interaction⁵

Zantac

RANITIDINE

A British advance from Glaxo

Prescribing Information


Zantac

RANITIDINE

Uses

Indications: Zantac Tablets are indicated for the treatment of duodenal ulcer, benign gastric ulcer, post-operative ulcer, reflux oesophagitis and the Zollinger-Ellison syndrome.

Mode of action: Zantac is a highly effective, rapidly acting histamine H₂-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Zantac has a relatively long duration of action and so a single dose effectively suppresses gastric acid secretion for twelve hours.



Dosage and administration

Adults: The usual dosage is one 150 mg tablet twice daily, taken in the morning and before retiring. It is not necessary to time the dose in relation to meals. In most cases of duodenal ulcer, benign gastric ulcer and post-operative ulcer, healing occurs in four weeks. In the small number of patients whose ulcers have not fully healed, healing usually occurs after a further course of treatment. Maintenance treatment at a reduced dosage of one 150 mg tablet at bedtime is recommended for patients who have responded to short-term therapy, particularly those with a history of recurrent ulcer. In the management of reflux oesophagitis, the recommended course of treatment is one 150 mg tablet twice daily for up to 8 weeks. In patients with Zollinger-Ellison syndrome, the starting dose is 150 mg three times daily and this may be increased, as necessary, to 900 mg per day.

Children: Experience with Zantac Tablets in children is limited and such use has not been fully evaluated in clinical studies. It has, however, been used successfully in children aged 8-18 years in doses up to 150 mg twice daily without adverse effect.

Contra-indications

There are no known contra-indications to the use of Zantac Tablets.

Precautions

Treatment with a histamine H₂-antagonist may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition.

Accordingly, where gastric ulcer is suspected the possibility of malignancy should be excluded before therapy with Zantac Tablets is instituted.

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased and prolonged in patients with severe renal failure. Accordingly, it is recommended that the therapeutic regimen for Zantac in such patients be 150 mg at night for 4 to 8 weeks. The same dose should be used for maintenance treatment should this be deemed necessary. If an ulcer has not healed after treatment for 4 to 8 weeks and the condition of the patient requires it, the standard dosage regimen of 150 mg twice daily should be instituted, followed, if need be, by maintenance treatment at 150 mg at night.

Although the incidence of adverse reactions in clinical trials of one year's duration and longer has been very low and no serious side effects have been reported with Zantac treatment, care should be taken to carry out periodic examinations of patients on prolonged maintenance treatment with the drug as a safeguard against the occurrence of unforeseeable consequences of drug treatment.

Like other drugs, Zantac should be used during pregnancy and nursing only if strictly necessary. Zantac is secreted in breast milk in lactating mothers but the clinical significance of this has not been fully evaluated.

Side effects

No serious adverse effects have been reported to date in patients treated with Zantac Tablets. There has been no clinically significant interference with endocrine, gonadal or liver function, nor has the drug adversely affected the central nervous system even in elderly patients.

Further information

Drug interactions: Ranitidine does not inhibit the cytochrome P450-linked mixed function oxygenase enzyme system in the liver and therefore does not interfere with the effects of the many drugs which are metabolised by this enzyme system. For example, there is no interaction with warfarin or diazepam.

Pharmacokinetics: Absorption of ranitidine after oral administration is rapid and peak plasma concentrations are usually achieved within two hours of administration. Absorption is not impaired by food or antacids. The elimination half-life of ranitidine is approximately two hours. Ranitidine is excreted via the kidneys mainly as the free drug and in minor amounts as metabolites. Its major metabolite is an N-oxide and there are smaller quantities of S-oxide and desmethyl ranitidine. The 24-hour urinary recovery of free ranitidine and its metabolites is about 40% with orally administered drug.

Use in renal transplants: Zantac has been used without adverse effect in patients with renal transplants.

Product licence number 0004/0279

Basic NHS cost (exclusive of VAT) 60 tablets £27.43.

References: 1. Data on file, Glaxo Group Research. 2. Bories, P *et al.*, *Lancet* 1980; 2 (8197):755. 3. Peden, N.R. *et al.*, *Acta Endocrinologica* 1981; 96:564-568. 4. Nelis, G.F. and Van de Meene, J.G.C., *Postgrad. Med J.* 1980; 56:478-480. 5. Henry, D.A. *et al.*, *Br Med J.* 1980; 2:775-777.

Glaxo

Zantac is a Glaxo trade mark.

Glaxo Laboratories Ltd., Greenford,
Middlesex UB6 0HE.

Reflux controlled!



Heartburn and regurgitation—strengthening the lower oesophageal sphincter is one of the primary goals of medical treatment.

Maxolon is clinically effective in increasing sphincter tone.

Maxolon—controlling heartburn by tightening the sphincter.

Prescribing Information

Indications

Heartburn, dyspepsia and flatulence associated with the following conditions e.g. Reflux oesophagitis, Gastritis, Hiatus hernia, Peptic ulcer. Nausea and vomiting associated with e.g. Gastro-intestinal disorders.

Adult dosage (Oral, IM or IV)

Total daily dosage of Maxolon, especially for children and young adults should not normally exceed 0.5 mg/kg body weight.

Adults: 10 mg three times daily

Young Adults (15-20 years): 5-10 mg three times daily, commencing at the lower dosage
For dosage in children, please consult Data Sheet.

Side effects and precautions

There are no absolute contra-indications to the use of Maxolon.

If vomiting persists the patient should be re-assessed to exclude the possibility of an underlying disorder, e.g. cerebral irritation.

Various extra-pyramidal reactions to Maxolon, usually of the dystonic type, have been reported. The incidence of these reactions in children and young adults may be increased if daily dosages higher than 0.5 mg/kg body weight are administered.

The majority of reactions occur within 36 hours of starting treatment and the effects usually disappear within 24 hours of withdrawal of the drug. Should treatment of a reaction be required, an anticholinergic anti-Parkinsonian drug, or a benzodiazepine may be used. Since extra-pyramidal symptoms may occur with both Maxolon and

phenothiazines, care should be exercised in the event of both drugs being prescribed concurrently.

Raised serum prolactin levels have been observed during metoclopramide therapy: this effect is similar to that noted with many other compounds.

Maxolon's action on the gastro-intestinal tract is antagonised by anticholinergics.

Although animal tests in several mammalian species have shown no teratogenic effects, treatment with Maxolon

is not advised during the first trimester of pregnancy.

Following operations such as pyloroplasty or gut anastomosis Maxolon therapy should be withheld for three or four days since vigorous muscular contractions may not help healing.

Availability and NHS prices

Tablets 10 mg (£9.78 for 100).
Syrup 5 mg/5 ml (£3.36 for 200 ml).
Ampoules for injection 10 mg (£2.69 for 10).
Paediatric Liquid 1 mg/1 ml (£1.52 for 15 ml).
Prices correct at August 1982.



Further information is available on request to the company

Beecham Research Laboratories
Brentford, England
Maxolon and the BRL logo are trade marks

PL 0038/0095 0098 5040 5041

References: 1. Br Med J (1979) 1: 3-4, 2. Gut (1973) 14: 275-279, 3. Gut (1973) 14: 380-382, 4. Gastroenterology (1975) 68 (5): 1114-1118, 5. Gastroenterology (1976) 70 (4): 484-487, 6. Anaesth Intens Care (1978) 6 (1): 26-29, 7. Gastroenterology (1980) 78 (5) pt 2: 1292, 8. Tijdschr Gastro-Enterol (1977) 20 (3): 155-162, 9. Dt Z Verdau-u-Stoffwechsellkr (1981) 41: 13-17, 10. Postgrad Med J (July Suppl. 1973) 104-106, 11. Z Gesund Inn Med. (1981): 122-124.

BRL 4033

NEW FROM BOOTS

For the treatment of peptic ulcer

Twice daily

GASTRO SELECTIVE
Gastrozepin[®]
pirenzepine



The new
gastro-selective
anti-secretory

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT...


- rely on acid reduction alone
- rely on pepsin reduction alone
- rely on mucosal protection alone
- profoundly affect intragastric pH

Gastrozepin DOES...

- relieve daytime pain
- relieve night-time pain
- reduce antacid intake
- heal peptic ulcers with one 50 mg tablet b.d.

Prescribing Information

Presentation:

White tablets each containing 50 mg of pirenzepine dihydrochloride, scored on one face with "G" on one side of the score, and "50" on the other. The obverse is impressed with the symbol 

Uses:

Gastrozepin is indicated in the treatment of gastric and duodenal ulcers.

50 mg at bedtime and in the morning before meals. In severe cases, the total daily dose may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months.

Contra-indications, Warnings etc.:

Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy although in animal experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. Side effects: occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdosage: entirely symptomatic. There is no specific antidote.

Basic NHS price:

50 mg tablets, 60 £20.50


Product Licence No:


50 mg tablets, PL0014/0260

Further information available on request



The Boots Company PLC, Nottingham, England
Gastrozepin® Trade Mark





COLPERMIN CALMS THE IRRITABLE BOWEL

enteric-coated peppermint oil

Now for the first time, the well-proven therapeutic agent peppermint oil, can be delivered direct to the colon.

Colpermin, a newly developed enteric-coated capsule, delivers the oil precisely

where it is needed. This provides an improved, rapid, and highly effective method of relieving spasmodic pain, distension and disturbed bowel habit - the dominant symptoms of the irritable bowel syndrome.

Presentation: Enteric coated gelatine capsule. Each contains 0.2 ml standardised peppermint oil B.P. Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe.

The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contraindications, Warnings, etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule.

Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and alaxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £10.00 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds. European Patent No. 0015334. UK Patent No. 2 006 011

Tillotts
LABORATORIES



PAX TAGAMETICA

'Tagamet' 400mg nocte can keep your duodenal ulcer patients free of relapse

Prescribing Information

Presentations 'Tagamet' Tablets, PL 0002/0063, each containing 200 mg cimetidine. 500, £72.75. 'Tagamet' Tablets, PL 0002/0092, each containing 400 mg cimetidine. 56, £16.30. 'Tagamet' Syrup, PL 0002/0073, containing 200 mg cimetidine per 5 ml. 200 ml, £7.86.

Indication Duodenal ulcer.

Dosage Usual dosage: Adults. Duodenal ulcer, 400 mg b.d. with breakfast and at bedtime, or 200 mg t.d.s. and 400 mg at bedtime (1.0 g/day) for at least 4 weeks. To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime for at least 6 months.

N.B. For full dosage instructions see Data Sheet.

Cautions Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants and phenytoin (see Data Sheet). Prolonged treatment: observe patients periodically. Exclude malignancy in gastric ulcer. Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation.

Adverse reactions Diarrhoea, dizziness, rash, tiredness. Rarely, mild gynaecomastia, reversible liver damage, confusional states (usually in the elderly or very ill), interstitial nephritis, acute pancreatitis.

Legal category POM.

22.9.82




Tagamet
cimetidine

puts you in control of gastric acid

SK&F Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY.


© 1982 Smith Kline & French Laboratories Limited. 'Tagamet' is a trade mark

.TG AD1152



Renaissance

Mediaeval Crusades



Era of Richard III

Bodily defence still relies on shields



NOW! A natural mucosal shield helps heal peptic ulcers!

CAVED-S® does what no other ulcer therapy can do: it increases the number of mucus-secreting cells¹ with virtually no side effects.² This protects the gastric mucosal barrier against damaging agents^{3, 4, 5} and reduces ulcer recurrence.⁶

An 88% healing rate in 12 weeks⁷ has been reported. Studies also confirm that CAVED-S offers comparable efficacy to cimetidine in healing gastric ulcers⁷ and comparable efficacy to ranitidine in healing duodenal ulcers.⁶

REFERENCES:

1. Van Marle I, Aarsen PN, Lind A, et al: Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. *Eur J Pharmacol* 72:219-225, 1981. 2. Cooke WM, Baron JH: Metabolic studies of deglycyrrhizinised liquorice in two patients with gastric ulcer. *Digestion* 4:264-268, 1971. 3. Rees WDW, Rhodes J, Wright JE, et al: Effect of deglycyrrhizinised liquorice on gastric mucosal damage by aspirin. *Scand J Gastroenterol* 14:605-607, 1979. 4. Morgan RJ, Nelson LM, Russell RI, et al: The effect of deglycyrrhizinised liquorice on the occurrence of aspirin and aspirin plus bile acid-induced gastric lesions, and aspirin absorption in rats, abstracted.

CAVED-S®

(deglycyrrhizinised liquorice, alum hydrox gel, mag carb, sod bic)

"The Mucosal Shield" for peptic ulcers



Henlow Trading Estate, Henlow, Bedfordshire. SG16 6DS.
Telephone 0462 813933 Telex: 82313 Tillab G.

PRESCRIBING INFORMATION

Presentation:
Brown tablets embossed 'CAVED-S', each containing:
Deglycyrrhizinised Liquorice 380 mg
Dried Aluminum hydroxide gel 100 mg
Magnesium carbonate 200 mg
Sodium bicarbonate 100 mg

Indications:
For the treatment of peptic ulcer and other allied conditions.

Dosage and Administration:

Adult dose for gastric ulcer:
2 tablets 3 times a day between meals.

Adult dose for duodenal ulcer:
Increase to 2 tablets 6 times a day between meals when necessary.

Prophylactic dose:

Gastric ulcer:
1 tablet 3 times a day, between meals.

Duodenal ulcer:
2 tablets 3 times a day, between meals.

Children's dosage 10-14 years:
half adult dose.

The tablets should be lightly chewed and swallowed with a drink of water, but in exceptional cases of objection to taste, the tablets should be broken into a few pieces and then swallowed with a drink of water. No additional antacids are necessary.

Contra-indications, warnings, etc:
Rare cases of mild diarrhoea can occur. No other side-effects have been reported.

CAVED-S should be used with caution in pregnancy.

Basic NHS Price:

60's—£1.83
240's—£10.12
600's—£22.76
PL0424/5000.




Gastroenterology 82:1134, 1982. 5. Morris TI, Calcraft BJ, Rhodes J, et al: Effect of a deglycyrrhizinised liquorice compound in the gastric mucosal barrier of the dog. *Digestion* 11:355-363, 1974. 6. McAdam WAP, Morgan AC, Pacsoo C, et al: A comparison between ranitidine and Caved-S in duodenal ulcer treatment, abstracted. Proceedings, World Congress of Gastroenterology, Stockholm, June 1982.

7. Morgan AC, McAdam WAP, Pacsoo C: Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut* 23:545-551, 1982.

KEY MED

COLONOSCOPY



THE OLYMPUS CF-LB3W COLONOSCOPE

The instrument of choice for total colonoscopy, with its wide field of view and two-stage flexibility for easy insertion.

There are seven other models in the Olympus colonoscope range, including the new PCF paediatric scope. Only with Olympus do you get this selection.

A demonstration of the CF-LB3W, or any of the other seven models, will show the superiority of this extensive range from Olympus.

Backed by KeyMed's second-to-none after-sales service and the unique first year **unconditional** guarantee.

The ideal combination of quality and service

OLYMPUS


KEY MED

Specialised Services to Medicine
KeyMed House Stock Road Southend-on-Sea Essex SS2 5QH
Telephone: (0702) 616333 Telex: 995283



Renaissance

Mediaeval Crusades



Era of Richard III

Bodily defence still relies on shields


NOW! A natural mucosal shield helps heal peptic ulcers!

CAVED-S* does what no other ulcer therapy can do: it increases the number of mucus-secreting cells¹ with virtually no side effects.² This protects the gastric mucosal barrier against damaging agents^{3,4,5} and reduces ulcer recurrence.⁶

An 88% healing rate in 12 weeks⁷ has been reported. Studies also confirm that CAVED-S offers comparable efficacy to cimetidine in healing gastric ulcers⁷ and comparable efficacy to ranitidine in healing duodenal ulcers.⁶

REFERENCES:

1. Van Marle J, Aarsen PN, Lind A, et al: Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. *Eur J Pharmacol* 72:219-225, 1981.
2. Cooke WM, Baron JH: Metabolic studies of deglycyrrhizinised liquorice in two patients with gastric ulcer. *Digestion* 4:264-268, 1971.
3. Rees WDW, Rhodes J, Wright JE, et al: Effect of deglycyrrhizinised liquorice on gastric mucosal damage by aspirin. *Scand J Gastroenterol* 14:605-607, 1979.
4. Morgan RJ, Nelson LM, Russell RI, et al: The effect of deglycyrrhizinised liquorice on the occurrence of aspirin and aspirin plus bile acid-induced gastric lesions, and aspirin absorption in rats, abstracted.



CAVED-S®

(deglycyrrhizinised liquorice, alum hydrox gel, mag carb, sod bic)

"The Mucosal Shield" for peptic ulcers



Henlow Trading Estate, Henlow, Bedfordshire. SG16 6DS.
Telephone 0462 813933 Telex: 82313 Tillab G.

PRESCRIBING INFORMATION

Presentation:

Brown tablets embossed 'CAVED-S', each containing:
Deglycyrrhizinised Liquorice 380 mg
Dried Aluminum hydroxide gel 100 mg
Magnesium carbonate 200 mg
Sodium bicarbonate 100 mg

Indications:

For the treatment of peptic ulcer and other allied conditions.

Dosage and Administration:

Adult dose for gastric ulcer:
2 tablets 3 times a day between meals.

Adult dose for duodenal ulcer:
Increase to 2 tablets 6 times a day between meals when necessary.

Prophylactic dose:

Gastric ulcer:

1 tablet 3 times a day, between meals.

Duodenal ulcer:

2 tablets 3 times a day, between meals.
Children's dosage 10-14 years:
half adult dose.

The tablets should be lightly chewed and swallowed with a drink of water, but in exceptional cases of objection to taste, the tablets should be broken into a few pieces and then swallowed with a drink of water. No additional antacids are necessary.

Contra-indications, warnings, etc:

Rare cases of mild diarrhoea can occur. No other side-effects have been reported.

CAVED-S should be used with caution in pregnancy.

Basic NHS Price:

60's—£2.83


240's—£10.12

600's—£22.76

PL0424/5000.




5. Morris TJ, Calcraft BJ, Rhodes J, et al: Effect of a deglycyrrhizinised liquorice compound in the gastric mucosal barrier of the dog. *Digestion* 11:355-363, 1974.
6. McAdam WAF, Morgan AC, Paccou C, et al: A comparison between ranitidine and Caved-S in duodenal ulcer treatment, abstracted. Proceedings, World Congress of Gastroenterology, Stockholm, June 1982.
7. Morgan AC, McAdam WAF, Paccou C: Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut* 23:545-551, 1982.



Renaissance

Mediaeval Crusades



Era of Richard III

Bodily defence still relies on shields


NOW! A natural mucosal shield helps heal peptic ulcers!

CAVED-S* does what no other ulcer therapy can do: it increases the number of mucus-secreting cells¹ with virtually no side effects.² This protects the gastric mucosal barrier against damaging agents^{3, 4, 5} and reduces ulcer recurrence.⁶

An 88% healing rate in 12 weeks⁷ has been reported. Studies also confirm that CAVED-S offers comparable efficacy to cimetidine in healing gastric ulcers⁷ and comparable efficacy to ranitidine in healing duodenal ulcers.⁶

REFERENCES:

1. Van Marle J, Aarsen PN, Lind A, et al: Deglycyrrhizinated liquorice (DGL) and the renewal of rat stomach epithelium. *Eur J Pharmacol* 72:219-225, 1981.
2. Cooke WM, Baron JH: Metabolic studies of deglycyrrhizinated liquorice in two patients with gastric ulcer. *Digestion* 4:264-268, 1971.
3. Rees WDW, Rhodes J, Wright JE, et al: Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. *Scand J Gastroenterol* 14:605-607, 1979.
4. Morgan RJ, Nelson LM, Russell RI, et al: The effect of deglycyrrhizinated liquorice on the occurrence of aspirin and aspirin plus bile acid-induced gastric lesions, and aspirin absorption in rats, abstracted.



CAVED-S®

(deglycyrrhizinated liquorice, alum hydrox gel, mag carb, sod bic)

"The Mucosal Shield" for peptic ulcers



Henlow Trading Estate, Henlow, Bedfordshire. SG16 6DS.
Telephone 0462 813933 Telex: 82313 Tillab G.

PRESCRIBING INFORMATION

Presentation:
Brown tablets embossed 'CAVED-S', each containing:
Deglycyrrhizinated Liquorice 380 mg
Dried Aluminum hydroxide gel 100 mg
Magnesium carbonate 200 mg
Sodium bicarbonate 100 mg

Indications:
For the treatment of peptic ulcer and other allied conditions.

Dosage and Administration:
Adult dose for gastric ulcer:
2 tablets 3 times a day between meals.

Adult dose for duodenal ulcer:
Increase to 2 tablets 6 times a day between meals when necessary.

Prophylactic dose:

Gastric ulcer:
1 tablet 3 times a day, between meals.

Duodenal ulcer:
2 tablets 3 times a day, between meals.

Children's dosage 10-14 years:
half adult dose.

The tablets should be lightly chewed and swallowed with a drink of water, but in exceptional cases of objection to taste, the tablets should be broken into a few pieces and then swallowed with a drink of water. No additional antacids are necessary.

Contra-indications, warnings, etc:
Rare cases of mild diarrhoea can occur. No other side-effects have been reported.


CAVED-S should be used with caution in pregnancy.

Basic NHS Prices:
60's — £2.83
240's — £10.12
600's — £22.76
PL0424/5000.



5. Morris TJ, Calcraft BJ, Rhodes J, et al: Effect of a deglycyrrhizinated liquorice compound in the gastric mucosal barrier of the dog. *Digestion* 11:355-363, 1974.
6. McAdam WAF, Morgan AC, Paccoco C, et al: A comparison between ranitidine and Caved-S in duodenal ulcer treatment, abstracted. Proceedings, World Congress of Gastroenterology, Stockholm, June 1982.
7. Morgan AC, McAdam WAF, Paccoco C: Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut* 23:545-551, 1982.

Reflux oesophagitis more than a little bit of acid



**Bile and pepsin
Oesophageal sensitivity
Inflammation
Erosion
Ulceration**


PYROGASTRONE

carbenoxolone/magnesium trisilicate/dried aluminium hydroxide gel

**more than an antacid
-a positive healing treatment**

Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories, Brit. Pat. No.1390683. Full information from Winthrop Laboratories, Surbiton-upon-Thames, Surrey. **WINTHROP**

A fresh approach to peptic ulcers



New **Antepsin**[®] sucralfate non-systemic ulcer healer

Prescribing Information

Presentation Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and embossed 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate. **Uses** For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration** For oral administration. **Adults** - Usual dose 1 gram 4 times a day. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required.

* ANTEPSIN is a registered Trade Mark

for relief of pain. **Contra-Indications, Precautions, Warnings, etc.** **Contra-Indications** There are no known contra-indications. **Precautions** 1. Concomitant administration with some oral anti-infectives such as tetracyclines may interfere with absorption of the latter. 2. The product should only be used with caution in patients with renal dysfunction. 3. As with all medicines, Antepsin should not be used in early pregnancy unless considered essential. **Side Effects** A low incidence of mild side effects, e.g. constipation, has been reported. **Legal Category** POM. **Package Quantities** Antepsin 1 gram - Securainers of 100. **Pharmaceutical Precautions** No special

Further information is available on request to the Company

requirements for storage are necessary. **Product Licence Numbers** PL No. 0607/0045 PA No. 149/4/2 Basic N.H.S. **Price** Average daily cost 50p.



Ayerst Laboratories Ltd.
South Way, Andover, Hampshire SP10 5LT.
Telephone: 0264 58711
Distributors in Ireland: Ayerst Laboratories Ltd.,
765 South Circular Road, Islandbridge, Dublin 8.

HEALING OF PEPTIC ULCER

"by restoring gastric
physiology to normal"¹

"Carbenoxolone . . . acts by restoring gastric physiology to normal in strengthening the mucosal barrier, rather than by creating a non-physiological situation of hypochlorhydria, such as antacids and H₂ receptor antagonists produce."¹

1. XI Int. Cong. Gastroenterology,
Hamburg, June 1980.

- Increased mucus production
- Reduced epithelial cell loss
- Reduced peptic secretion and activity



BIOGASTRONE

carbenoxolone
for gastric ulcer



DUOGASTRONE

carbenoxolone
for duodenal ulcer



Further information available from Winthrop Laboratories, Surbiton-upon-Thames,
Surrey KT6 4PH. See prescribing data overleaf.

WINTHROP

BIOGASTRONE

carbenoxolone
for gastric ulcer

Carbenoxolone sodium BP 50 mg tablets.
PL 0071/5902. Bottles of 100. Basic NHS cost:
1 week's treatment £2.63 (21 tablets) – £5.26
(42 tablets).

Adult dose: 2 tablets t.i.d. after meals for the first
week then 1 tablet t.i.d. until ulcer is healed
(usually 4-6 weeks).

DUOGASTRONE

carbenoxolone
for duodenal ulcer

Carbenoxolone sodium BP 50 mg
position-release capsules. Bottles of 28.
PL 0071/5903. Basic NHS cost: 1 day's treatment
(4 capsules) £1.01.

Adult dose: 1 capsule swallowed whole and
unbroken with liquid q.i.d., 15-30 minutes before
meals. Patients may continue to take antacids
but anticholinergic drugs should be
discontinued. Treatment should continue for
6-12 weeks.

**Safety factors: Biogastrone and
Duogastrone**

Contra-indications. Severe cardiac, renal or
hepatic failure. Patients on digitalis therapy,
unless serum electrolyte levels are monitored
weekly and measures taken to prevent the
development of hypokalaemia.

Precautions. Special care should be exercised
with patients pre-disposed to sodium and water
retention, potassium loss and hypertension (e.g.
the elderly and those with cardiac, renal or
hepatic disease) since carbenoxolone can
induce similar changes. Regular monitoring of
weight and blood pressure, which should
indicate such effects, is advisable for all patients.

A thiazide diuretic should be administered if
oedema or hypertension occurs.

(Spironolactone or amiloride should not be
used because they hinder the therapeutic
action of carbenoxolone). Potassium loss
should be corrected by the administration
of oral supplements. No teratogenic effects
have been reported with carbenoxolone
sodium, but careful consideration should be
given before prescribing Biogastrone or
Duogastrone for women who may become
pregnant.

Biogastrone and Duogastrone are registered
trade marks.

Made under licence from Biorex Laboratories.
Further information available from Winthrop
Laboratories, Surbiton-upon-Thames, Surrey
KT6 4PH.

This Publication is available in Microform.



University Microfilms International

Please send additional information

for _____
(name of publication)

Name _____

Institution _____

Street _____

City _____

State _____ Zip _____

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106

SCANDINAVIAN JOURNAL OF Gastroenterology

CONTENTS	Volume 17, No. 8, November 1982
<i>Review: Hepatobiliary Disease in Ulcerative Colitis</i> E. Schrupf & E. Gjone	961
<i>A Prospective Reappraisal of Emergency Endoscopy in Patients with Portal Hypertension</i> K. J. Mitchell, B. R. D. MacDougall, D. B. A. Silk & R. Williams	965
<i>Duodenal Somatostatin in Coeliac Disease</i> K. Sjölund, R. Hakanson, G. Lundqvist & F. Sundler	969
<i>Occurrence of Gastric Mucosal Erosions in Association with Other Upper Gastrointestinal Diseases, Especially Peptic Ulcer Disease, As Revealed by Elective Gastroscopy</i> A.-L. Karvonen	977
<i>Relationships between Hydrogen (H₂) and Methane (CH₄) Production in Man</i> A. Bjørneklett & E. Jenssen	985
<i>Relationship between Preoperative Basal Serum Gastrin Concentration and Acid Secretion after Proximal Gastric Vagotomy</i> J. H. Steen, N. Steen, M. Herning & P. M. Christiansen	993
<i>Comparative Diagnostic Accuracy of Four Tubeless Pancreatic Function Tests in Chronic Pancreatitis</i> R. W. Ammann, H. Bühler & P. Pei	997
<i>Long-Term Treatment of Duodenal Ulcer with Trimipramine. A Double-Blind Study</i> K. Valnes, J. Myren, S. Wetterhus, S. Larsen, S. Dyb, E. F. Ellekjær, L. Halvorsen & N. Hovdenak	1003
<i>Peritoneovenous Shunting for Intractable Ascites</i> P. Gullstrand, A. Alwmark, B. Börjesson, B. Joelsson & S. Bengmark	1009
<i>The Effect of a Standardized Work Load on 'Liver Tests' in Patients with Chronic Active Hepatitis</i> S. Ritland, N. E. Foss & S. Skrede	1013
<i>A Semiquantitative Histological Method to Estimate Acute and Chronic Radiation Injury in the Small Intestine of the Cat</i> B. Eriksson, L. Johnson & C. Rubio	1017
<i>Gastric Blood Flow and Distribution in Anesthetized Cat and Man As Studied by an Inert Gas Elimination Method</i> L. E. Ivarsson, N. Darle, L. Hultén, J. Lindhagen & O. Lundgren	1025
<i>Gastric Blood Flow and Distribution: The Effect of Pentagastrin in Anesthetized Cat and Man As Studied by an Inert Gas Elimination Method</i> L. E. Ivarsson, N. Darle, L. Hultén, J. Lindhagen & O. Lundgren	1037
<i>Abnormalities of T Cells in Patients with Ulcerative Colitis. FACS Analysis of Peripheral Lymphocytes</i> Y. Shiratori, T. Hirano & K. Okumura	1049
<i>Subcellular Fractionation of Human Intestinal Mucosa by Large-Scale Zonal Centrifugation. Localization of the Lysophospholipase Activity in Distal Ileum</i> T. Bolin, K.-E. Magnusson, R. Sjö Dahl & C. Tagesson	1057
<i>Gastric Emptying after Peptic Ulcer Surgery. Some Pathophysiological Mechanisms of the Dumping Syndrome</i> O. Lawaetz, Y. Aritas, A. M. Blackburn & D. N. L. Ralphs	1065
<i>Changes in the Pattern of Peptic Ulcer Disease in the Northern Part of Norway between 1946 and 1981</i> H. Østensen, P. G. Burhol, O. Bonnevie & K. D. Bolz	1073
<i>A Quantitative Method of Estimating Inflammation in the Rectal Mucosa. II. Normal Limits in Symptomatic Patients</i> C. A. Rubio, C. Johansson & Y. Kock	1077
<i>A Quantitative Method of Estimating Inflammation in the Rectal Mucosa. III. Chronic Ulcerative Colitis</i> C. A. Rubio, C. Johansson & Y. Kock	1083
Erratum	1088
Index for Volume 17, 1982	

Abstracted in *Excerpta Medica*
Indexed in *Current Contents and Index Medicus*

ISSN 0036-5521

Annual subscription (eight issues per year) NOK 780,-/USD\$142.00

Publisher: Universitetsforlaget, P.O. Box 2959 Tøyen, Oslo 6, Norway.

U.S. address: P.O. Box 258, Irvington-on-Hudson, NY 10533, USA.